Study wrapper · #677
ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.
Editor's note
Another entry in the same lab's transcriptomic series: in a rat transient-MCAO stroke model, RNA-seq at 24 hours found roughly 3,774 ischemia-related differentially expressed genes, and Semax (ACTH(4-7)PGP) reduced ischemia-driven distortion for over 1,100 immune- and neurosignaling-related genes. The authors tie this to a previously observed histological neuroprotective effect and show the peptide's action varies with time after occlusion. As mechanistic preclinical work it strengthens internal consistency of the Semax stroke story but adds no clinical or behavioral endpoint. Because these studies largely originate from one group and one model, independent replication would raise confidence. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
This rat study looked at how a stroke changes gene activity in the frontal cortex, the brain tissue bordering the damaged zone, and whether the peptide Semax counteracts those changes. One day after a temporary blockage of a brain artery, the researchers found thousands of genes with altered activity. Semax nudged more than a thousand of them, mostly involved in immune responses and nerve-cell signaling, back toward normal. The team connected this to an earlier finding that Semax reduced visible tissue damage at the same time point, suggesting the gene changes underlie that protection. They also showed the peptide's effects depend on how much time has passed since the stroke. This is detailed laboratory work in rats meant to explain mechanism and help pick future drug candidates; it does not test Semax as a treatment in humans.